Hydroxychloroquine: proposed risk factors for Retinopathy #EULAR2019 https://t.co/WkyNZ4GPVr

Mease: SEAM study MTX vs Etanercept in PsA. ETA effects > MTX with no additional benefit of combination. But some MTX benefit (note no PBO arm). Interesting separation between MTX<ETA for PASDAS (muli domain) but not DAPSA (joints only) #Eular2019 @RheumNow https://t.co/WSUlGE7NEf

#Gout patients tend not to tell doctors impact of gout on quality of life 👉🏼43% #mentalhealth 👉🏼27% impact on family 👉🏼26% relationship with partners ➡️🔟% lost job or retired due to gout by Meulemeester #EULAR2019 https://t.co/fyrAyvpaYO

Mease: Filgotinib (selective JAK1i) in active PsA ph2. Promising data. Interesting and informative way to present individual participant level data over time rather than just aggregate data - may be more useful for clinicians and patients to understand. #EULAR2019 @RheumNow https://t.co/B0pLODWGJ9

So, what are we left with? Some patients get another year free of remission - that’s good. TCZ is steroid-sparing - that’s good. Still questions about longer follow-up and sequelae, and a year’s therapy doesn’t cure everyone. It’s not a panacea for all GCA ills, but it’s a start! https://t.co/6AiIQLnLFN

Well it’s not all she wrote when flares come along, flares can be treated - some data on how to fix them, but beware the channeling bias https://t.co/o0rwYr1Ll7

McInnes: Machine-learning separates out 13 clusters of PsA in RCT population (i.e. already selected). Offers opportunities to reduce some of the massive heterogeneity in PsA to help inform biomarker studies and future precision medicine strategies. #Eular2019 @RheumNow https://t.co/h3Otp4Oq8U

For new knee inflammatory arthritis nearly 60% are in full remission at one year whereas 10% spread to progressive arthritis and 30% have persistent knee IA. Leiden Early arthritis cohort #EULAR2019 @RheumNow https://t.co/ZuLI1OCfhT https://t.co/x2Tr1tF0j6

Poster THU0687 FMF and schizo each increase mortality and worse if co-occurrence #EULAR2019 @RheumNow https://t.co/nVfiw25Lzf https://t.co/U9KELLJzVD

Be sure not to miss our symposium tomorrow morning: ‘The Patient Perspective: Addressing Challenges Facing Women with #axSpA and PsA’. Join us tomorrow! #EULAR2019 #psoriaticarthritis https://t.co/G0NkmblAhI

Checkpoint inhibitor use is exploding in cancer Rx. Big data review of 13000 cases of immune mediated reactions are mostly endo, GI and pulmonary and NOT rheumatic THUS0628 #EULAR2019 @RheumNow https://t.co/iYO8t6ALBx

Olofsson, Sweden: important topic of unacceptable residual pain despite biologic in PsA with >80% of this pain despite good inflammatory control #Eular2019 @RheumNow https://t.co/vjiakjCKR0